Nanox.AI vs Ultromics EchoGo
EchoGo Heart Failure flags HFpEF from one apical four-chamber clip in adults over 25 with ejection fraction of 50% or more (K240013, decided September 23, 2024), and the vendor states 90.3% sensitivity and 86.1% specificity from that filing. EchoGo Amyloidosis (K240860) screens adults 65 and over with heart failure. Ultromics lists HIPAA, GDPR and ISO/IEC 27001:2022 on its trust center, and CPT Category III code 0932T is assigned to the heart failure tool.
Ultromics reads transthoracic echo and Nanox's three listed solutions all read CT, so an echo lab and a CT radiology department are different buyers. Nanox's HealthCCSng takes non-contrast chest CT and returns a calcium category, and the AI page says results reach the radiology report and EMR through PACS, EMR and report-system connections without naming brands. Radiology departments mining routine CT for calcium buy it, and cardiology services with an echo lab buy Ultromics.
Radiology · Reviewed November 2, 2026
Nanox.AI
by Nano-X Imaging
CT AI for opportunistic screening: coronary calcium, vertebral fractures and liver fat on routine CT scans, for radiology departments.
Ultromics EchoGo
by Ultromics
FDA-cleared AI on echocardiograms that flags heart failure with preserved ejection fraction and screens for cardiac amyloidosis.
When to pick each one
Nanox.AI
- Coronary calcium category from non-contrast chest CT
- Results go into radiology report and EMR
Ultromics EchoGo
- HFpEF flag from one apical four-chamber echo clip
- Amyloidosis screen for adults 65 and over with heart failure
- HIPAA and ISO/IEC 27001:2022 on trust center
Score
Each row shows points earned of points available under the published rubric.
Nanox.AI
35of 100
Ultromics EchoGo
42of 100
| Dimension | Nanox.AI | Ultromics EchoGo | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 18.2 | 0 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Nanox.AI
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Ultromics EchoGo
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Nanox.AI
FDA decisions
K241440 (opens in new tab)510(k)2024-08-19
HealthCCSng
K233080 (opens in new tab)510(k)2024-02-08
HealthFLD
K213944 (opens in new tab)510(k)2022-04-22
HealthOST
K211803 (opens in new tab)510(k)2021-12-15
HealthPPT
K210085 (opens in new tab)510(k)2021-09-15
HealthCCSng
Show 7 more
K202487 (opens in new tab)510(k)2020-12-04
HealthJOINT
K200905 (opens in new tab)510(k)2020-07-16
HealthMammo
K192901 (opens in new tab)510(k)2020-05-12
HealthVCF
K192320 (opens in new tab)510(k)2019-11-26
HealthCXR
K190424 (opens in new tab)510(k)2019-06-13
HealthICH
K190362 (opens in new tab)510(k)2019-05-06
HealthPNX
K172983 (opens in new tab)510(k)2018-06-13
HealthCCS
Ultromics EchoGo
FDA decisions
K240860 (opens in new tab)510(k)2024-11-15
EchoGo Amyloidosis (1.0)
K240013 (opens in new tab)510(k)2024-09-23
EchoGo Heart Failure (2.0)
K222463 (opens in new tab)510(k)2022-11-23
EchoGo Heart Failure 1.0
K213275 (opens in new tab)510(k)2021-12-20
EchoGo Core (2.0)
K201555 (opens in new tab)510(k)2020-12-18
EchoGo Pro v1.0.2
Show 1 more
K191171 (opens in new tab)510(k)2019-11-13
EchoGo Core
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Nanox.AI | Ultromics EchoGo |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | n/a | GB |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.